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Abstract
Objectives: The metabolic syndrome is a cluster of cardiovascular risk factors leading to an increased risk for the
subsequent development of diabetes and cardiovascular morbidity and mortality. Blocking the renin-angiotensin system
has been shown to prevent cardiovascular disease and delay the onset of diabetes. Irbesartan is an angiotensin receptor
blocker (ARB) which has been shown to possess peroxisome proliferator-activated receptor gamma (PPARγ) activating
properties, and to have a favorable metabolic profile. Current discussion is whether the addition of small doses of
hydrochlorothiazide changes this profile. Therefore the efficacy, safety and metabolic profile of Irbesartan either as
monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational
cohort in primary care.
Research design and methods: Multicenter, prospective, two-armed, post authorization study over 9 months in
14,200 patients with uncontrolled hypertension with and without the metabolic syndrome (doctors' diagnosis based on
the Adult Treatment Panel III criteria 2001). Blood pressure was measured sphygmomanometrically and cardiovascular
risk factors making up the criteria for the metabolic syndrome were assessed.
Main outcome measures: Systolic (SBP) and diastolic (DBP) blood pressure reduction, – response, and –
normalization (systolic and diastolic), changes in fasting glucose, waist circumference (abdominal obesity), serum
triglycerides and HDL cholesterol as well as the proportion of patients fulfilling the criteria for the metabolic syndrome.
Number and nature of adverse events (AEs).
Results: After 9 month the use of Irbesartan in monotherapy resulted in a significant reduction of blood pressure (SBP: -
26.3 ± 10.1 mmHg/DBP-13.0 ± 6.6 mmHg, both p < 0.0001) in patients with the metabolic syndrome. This was
accompanied by a reduction in cardiovascular risk factors: HDL cholesterol (+3.6 ± 7.2 mg/dl in men, +3.8 ± 6.5 mg/dl
in women, both p < 0.0001), serum triglycerides (-28.6 ± 52.1 mg/dl, p < 0.0001), fasting blood glucose (-8.4 ± 25.1 mg/
dl, p < 0.0001) and waist circumference (-2.4 ± 11.9 cm in men, -1.2 ± 14.2 in women, both p < 0.0001) were significantly
improved. Irbesartan combination therapy (12.5 mg HCTZ) in patients with the metabolic syndrome: blood pressure
reduction (SBP: -27.5 ± 10.1 mmHg/DBP: -14.1 ± 6.6 mmHg, both p < 0.0001), improvement in HDL cholesterol (+4.0
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± 6.8 mg/dl in men, +3.4 ± 6.8 in women, both p < 0.0001), triglycerides (-34.1 ± 52.6 mg/dl, p < 0.0001), fasting blood
glucose (-10.0 ± 24.7, p < 0.0001) and waist circumference (-3.2 ± 12.7 cm in men, -1.7 ± 14.4 in women, both p <
0.0001). Tolerability was excellent: only 0.6% of patients experienced an AE.
Conclusion: There was a significant improvement in blood pressure and metabolic risk factors as a result of Irbesartan
treatment. There was no evidence of a difference between monotherapy and combination therapy with regard to the
cardiovascular risk profile.
Background
"Metabolic syndrome" describes the presence of a cluster
of cardiovascular risk factors including hypertension,
insulin resistance or glucose intolerance, visceral obesity
and atherogenic dyslipidemia, resulting in a prothrom-
botic and proinflammatory state [1,2]. The presence of the
metabolic syndrome predicts a two- to four-fold increase
in the risk of cardiovascular disease and death [3,4], and
the risk of developing type 2 diabetes is increased five- to
nine-fold [5,6].
The lack of a universally agreed definition has compli-
cated the epidemiologic research on the prevalence of this
syndrome [7]. Nevertheless, it has been proposed that the
metabolic syndrome is present in about 10–25% of indi-
viduals in the industrialized world [5,8]. The availability
of high-calorie, low-fiber foods and more sedentary life-
styles are also leading to an increase in the prevalence of
the metabolic syndrome in developing countries [9].
Recent data from the German Metabolic and Cardiovascu-
lar Risk Study (GEMCAS) [10] indicated a prevalence of
28% for the German primary care population (34% in
men, 24% in women) using the AHA, NHLBI Definition
2005 [7] – a population that is also investigated in the cur-
rent study.
In general, risk factors of the metabolic syndrome are
treated separately and there is currently no available treat-
ment that targets all components. Some classes of antihy-
pertensive drugs, notably calcium channel blockers,
angiotensin converting enzyme (ACE) inhibitors and
angiotensin II receptor blockers (ARBs), have been shown
to reduce or at least not to increase the incidence of new-
onset diabetes, particularly as compared to diuretics and
betablockers [11]. This suggests that antihypertensive
agents may have differential effects on hyperglycemia in
patients with metabolic syndrome. Furthermore, recent
work has shown that Irbesartan and Telmisartan act as
partial peroxisome proliferator-activated receptor gamma
(PPARγ) agonists at concentrations that are achievable
with oral doses recommended for the treatment of hyper-
tension, thus suggesting their insulin-sensitizing effect
[12-14]. Comparing the two ARBs Telmisartan and Losar-
tan in a clinical study, Vitale et al. were recently able to
show that Telmisartan, unlike Losartan, was able to
reduce free plasma glucose, free plasma insulin, and
HbA1c, suggesting a general intra class difference in the
potential for improving the metabolic abnormalities
present in patients with the metabolic syndrome [15].
It was therefore the aim of the present analysis of the post
authorization study Treat to Target to investigate in more
detail the influence of the PPARγ activating ARB Irbe-
sartan with or without HCTZ on metabolic parameters. It
was conducted as an observational study in primary care
in order to acquire a broad spectrum of patients in clinical
practice. The intention was to investigate three core ques-
tions: 1) Characteristics and comorbidity pattern of
patients with the metabolic syndrome, 2) Blood pressure
response to Irbesartan alone and in combination with
hydrochlorothiazide (including response, overall and
systolic/diastolic normalization), and 3) accompanying
changes in cardiovascular risk factors (components of the




This was a 9-month, multicenter, open-label, two-armed,
prospective, observational post-authorization survey
(PAS), which was conducted by 3,609 general physicians,
practitioners and internists (GPs) throughout Germany.
This specific study type is regulated by the German Drug
Law (AMG) §67(6) and is primarily intended to gather
knowledge about the safety and efficacy of marketed
drugs in daily practice. The federal panel doctors' associa-
tions as well as the higher authorities were duly notified
about this investigation. The participating GPs received a
small remuneration for the documentation of each
patient, which is common practice for this type of PAS.
Importantly, as in any PAS, the protocol stipulated no
interventions different from routine treatment. In a PAS
the drug can only be prescribed in the labeled indication
according to the Summary of Product Characteristics
(SmPC). The procedures and decisions of the physicians
were not influenced and the physicians were completely
free to select which patients to treat with the licensed drug
being studied, which diagnostic measurements they used,
and the way in which they monitored the course of treat-
ment or which concurrent or additional medication they
prescribed. Due to the non-interventional type of the
study, no ethics committee approval or patient informedCardiovascular Diabetology 2007, 6:12 http://www.cardiab.com/content/6/1/12
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consent has to be obtained in accordance with the Ger-
man local laws and regulations. The participating physi-
cians collected data on the background characteristics of
the patients and on key efficacy variables and adverse
events (AEs) and documented them in case report forms
(CRFs). If any serious adverse events (SAEs) occurred, the
GPs were obliged to report them by completing a form
within 24 hours and transmitting it to the manufacturer,
who then forwarded the report in a standardized format
to the relevant authority (Bundesinstitut für Arzneimittel
und Medizinprodukte, Bonn, Germany). The collected
data, SAE forms and CRFs were not consistently verified in
comparison with the source data in the patient files, but
the forms were systematically screened for plausibility and
completeness.
Patients and Study Conduct
Patients with an indication for treatment with Irbesartan
with or without HCTZ were selected by the GPs, using a
cohort approach. Only adult patients could be included
(18 years), and there were no additional exclusion criteria
regarding concomitant medication or concomitant dis-
eases except those specified in the SmPC. Patients were
stratified into the metabolic syndrome cohort if they ful-
filled the criteria set forth by the National Cholesterol
Education Program Expert Panel (NCEP) in 2001 [2],
which applied to 9281 patients. 4919 patients with
uncontrolled arterial hypertension without the metabolic
syndrome served as controls (the intention was to have a
2 : 1 distribution). The GPs selected patients with uncon-
trolled arterial hypertension for once daily treatment with
Irbesartan (Aprovel™ 75, 150 or 300 mg) as monotherapy
or in a combination with 12.5 mg hydrochlorothiazide
(HCTZ) (CoAprovel™ 150/12.5 or 300/12.5 Sanofi-
Aventis Deutschland GmbH, Berlin). The prescription of
additional antihypertensive agents was allowed, as was
the discontinuation of other medications, if necessary.
There were no stipulations regarding BP targets. However
a considerable percentage of German doctors follow the
established guidelines of the German Hypertension
League, which are < 140/90 mmHg for all patients except
patients with diabetes, for whom < 130/80 mmHg applies
[16].
The parameters documented in the study included demo-
graphic characteristics (initials, age, sex, weight and
height, hip and waist circumference, familial cardiovascu-
lar disease and smoking status), medical diagnoses (dia-
betes, arterial hypertension with the number of years
present and known microalbuminuria/proteinuria).
Blood pressure was to be taken as a mean of three sphyg-
momanometric measurements, and pulse rate (beats per
minute, bpm) and the respective target blood pressure for
each patient were also to be recorded. If available from the
charts, the following laboratory parameters were col-
lected: fasting blood glucose, HbA1c, triglycerides, HDL
and LDL cholesterol, creatinine and urinary albumin. In
addition, concomitant disease was documented: stroke/
transient ischemic attack (TIA), neuropathy, coronary
heart disease (CHD), heart failure, previous myocardial
infarction (MI), aorto-coronary venous bypass operation
(ACVB), retinopathy, previous PTCA/stent, left ventricular
hypertrophy (LVH), lipid disorders and peripheral arterial
disease (PAD). Antihypertensive therapy within the previ-
ous 12 months was documented as well as the modifica-
tions after switching medications at the baseline visit.
After 3 and 9 months blood pressure measurements were
repeated and the following parameters obtained if availa-
ble: weight, hip and waist circumference, pulse, triglycer-
ides, HDL and LDL cholesterol, fasting blood glucose,
HbA1c, creatinine and urinary albumin. Modifications of
antihypertensive therapy were documented and whether
patients reached blood pressure targets was determined.
The following features of AEs were recorded if these
occurred: description, first occurrence, grade of severity,
outcome of events (recovered, recovered with sequelae,
unresolved), likelihood of causal relationship (possible,
probable, improbable, no relationship).
Statistical Analyses
According to the predefined statistical analysis plan, the
statistical analysis was performed descriptively and was
interpreted in an explorative way. Comparisons were
made for blood pressure and proportions of patients with
components of the metabolic syndrome positive between
baseline and the two post-baseline visits. The absolute
and relative frequencies of AEs and the efficacy and toler-
ability ratings were reported. Post-hoc analyses for sub-
groups defined by gender, BMI, waist circumference,
duration of hypertension, strength of antihypertensive
response, and previous and concomitant antihypertensive
treatment, respectively, were carried out. The analysis of
data was performed with the statistical software package
SAS, version 8.2. Test applied are indicated in the legend
of tables and figures [17]. Regarding safety, the trial was
adequately sized to identify rare AEs, i.e. those that may
not have been detected in previous clinical studies, (inci-
dence 1: 1,000) with a probability of > 99% and very rare
events (incidence 1: 10,000) with a probability of > 75%.
Results
Baseline Characteristics
In the observational period between January 2005 and
July 2006, a total of 14,200 patients were documented, of
which 9281 were diagnosed as having the metabolic syn-
drome (MS); 4919 patients served as controls. Men and
women were balanced (52.4 vs. 46.3% in patients without
the MS, 51.8 vs. 47.9% in patients with the MS, with aCardiovascular Diabetology 2007, 6:12 http://www.cardiab.com/content/6/1/12
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mean age of 61.2 ± 11.6 (without MS) and 62.4 ± 10.2
years (with MS). Mean BMI was 26.8 ± 3.7 kg/m2 without
and 31.2 ± 5.0 kg/m2 with the MS. Accordingly, both male
and female patients with the MS had a higher waist cir-
cumference: men 111.3 ± 12.8 vs. 96.9 ± 10.2 cm and
women 100.7 ± 14.6 vs. 85.9 ± 11.9 cm.
Figure 1 shows the risk factor pattern of patients with the
MS in comparison to patients without. While an elevated
blood pressure was an inclusion criterion for this observa-
tional study (e.g. ~ 100% default) all other risk factors are
substantially increased in patients with the metabolic syn-
drome – abdominal obesity (77.5 vs. 19.6%, p < 0.0001)
and fasting glucose (53.8 vs. 0.0%, p < 0.0001) being the
most apparent difference between the two groups.
Comorbidity pattern of patients with or without the 
metabolic syndrome
In line with the documentation of cardiovascular risk fac-
tors is the observation that patients that have been
assigned the diagnosis metabolic syndrome by their treat-
ing physicians have many more comorbid conditions
than their controls (see figure 2). There are far fewer
patients with no comorbidities (19.3% vs. 53.8%, p <
0.0001). In general, the prevalence of the comorbidities
listed is at least twice as high as in control patients, retin-
opathy being increased five-fold (6.0 vs. 1.2%, p <
0.0001) and neuropathy about seven-fold (9.7 vs. 1.4%, p
< 0.0001).
Antihypertensive medication
At baseline, patients with the metabolic syndrome were
receiving more medication to lower blood pressure as
compared to their corresponding controls (see table 1). In
particular, ACE-inhibitors (+ 11.3%), diuretics (+17.1%)
and calcium antagonists (+8.9%) were being prescribed
more frequently at the time of the baseline visit (before
any change in medication, p < 0.0001). When switching
to the ARB medication, in most cases previous ACE inhib-
itor use is discontinued (59.3 down to 7.7% in patients
with the MS) but also diuretics are withdrawn in many
cases. In line with this, the most frequently used new ther-
apy is Irbesartan 300 mg/12.5 mg HCTZ, which is insti-
tuted in more than 60% of cases with the MS. In general,
approximately 80% of all patients receive 300 mg Irbe-
sartan – either alone or in combination with HCTZ.
Metabolic risk factors – Effects in patients treated with 
Irbesartan with or without the metabolic syndrome
Comparing the effect of Irbesartan (alone or in combina-
tion with HCTZ) on metabolic risk factors in patients with
vs. in patients without the metabolic syndrome, remarka-
ble differences can be found. While there is no effect of
treatment on HDL cholesterol in women without the met-
abolic syndrome (-0.3 ± 5.8 mg/dL, p = ns), in men there
is an increase of 0.8 ± 6.2 mg/dL (p < 0.0001). In patients
with the metabolic syndrome there is a significant
increase in both genders (+3.3 ± 6.7 mg/dL in women, p
< 0.0001 and +3.8 ± 7.0 mg/dL in men, p < 0.0001). Like-
wise there is no clinical benefit on fasting plasma glucose
in normal patients (+0.3 ± 13.5 mg/dL, p = ns after 3
months; +1.1 ± 15.0 mg/dL, p < 0.05 after 9 months) as
compared to metabolic syndrome patients (-9.0 ± 25.0
mg/dL, p < 0.0001 after 9 months). All other comparisons
are significant and show an improvement in the parame-
ters documented, but still, patients with the metabolic
syndrome seem to benefit more from Irbesartan treatment
than patients without (see table 2).
Components of the metabolic syndrome – Irbesartan alone 
or in combination with HCTZ
To assess the suitability of Irbesartan combination therapy
with HCTZ for use in patients with the metabolic syn-
drome the same parameters as above were assessed and
patients on monotherapy were compared with those on
the combination. There were consistent and highly signif-
icant (p < 0.0001) reductions of blood pressure, fasting
plasma glucose, abdominal obesity, triglycerides and an
increase in HDL cholesterol after 9 months of treatment
with Irbesartan monotherapy as well as with the combina-
tion therapy (for individual figures see table 3). While
individual figures differed slightly between groups there
was no consistent trend to signal untoward effects of the
combination therapy with HCTZ.
Consequently there was a marked reduction in the
number of patients fulfilling the criteria for the metabolic
syndrome (-29.5% for patients on monotherapy, -23.4%
for patients on fixed combinations with HCTZ) irrespec-
tive of whether hypertension was considered or not. Fig-
ure 3 shows that while almost all patients were considered
to have the metabolic syndrome (based on baseline risk
factor prevalence (95.1% in the group with monotherapy,
95.8% in the combination group), the proportion of
patients not fulfilling the criteria for the metabolic syn-
drome rose from 4.9% and 4.2% respectively to 34.3%
(monotherapy) and 27.5% (combination).
Side effects
The rate of AEs was very low. Only 141 AEs were noted in
88 patients (0.62% of all patients). 65 SAEs were noted in
34 patients (0.24%). There were 17 deaths in 14,200
patients during a study period of 9 months. For details see
Table 4.
Discussion
In the present study 14,200 unselected primary care
patients with or without the metabolic syndrome were
treated with Irbesartan alone or in combination with 12.5
mg HCTZ. The observation of the 9-month treatmentCardiovascular Diabetology 2007, 6:12 http://www.cardiab.com/content/6/1/12
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a&b: Risk factor distribution (Figure 1a) and presence of metabolic risk factors in patients with or without the metabolic syn- drome (Figure 1b) Figure 1
a&b: Risk factor distribution (Figure 1a) and presence of metabolic risk factors in patients with or without the metabolic syn-
drome (Figure 1b). Fasting plasma glucose 110 mg/dL; Abdominal obesity > 102 cm in men/> 88 cm in women; Triglycerides ≥ 
150 mg/dL; Blood Pressure ≥ 130/≥ 85 mmHg; HDL cholesterol: < 40 mg/dL in men, < 50 mg/dL in women; Met (+) – Patients 
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period and the comparison of monotherapy and combi-
nation therapy in terms of blood pressure reduction and
interference with cardiovascular risk factors yielded the
following results: 1) There was a significant improvement
in metabolic risk factors as a result of Irbesartan treat-
ment. 2) There was no evidence of a difference between
monotherapy and combination therapy with regard to the
cardiovascular risk profile. 3) There was a pronounced
blood pressure lowering effect with both monotherapy
and combination therapy, with a slightly better blood
pressure response in patients without the metabolic syn-
drome. 4) There was a favorable reduction in the number
of tablets to be taken.
Cardiovascular risk profile
During the 9-month study period an improvement in
metabolic parameters was noted that was substantial for
fasting plasma glucose, triglycerides and HDL cholesterol
(patients with the metabolic syndrome > patients with-
out). Interestingly, even a reduction in abdominal obesity
was noted; this was small, but resulted in a reduction in
waist circumference of up to 3.2 cm (in patients on Irbe-
sartan/HCTZ combination therapy after 9 months).
It cannot be ruled out that the observed effects are due to
the study conduct that may have improved patient com-
pliance, but several lines of reasoning point toward a met-
abolic profile of Irbesartan that may be in part responsible
for these results. 1) Both Telmisartan and Irbesartan acti-
vate the PPARγ receptor [12,14] and the EC50 value for
transactivation is about 27 μmol/l for Irbesartan [14].
Clinical evidence for an insulin sensitizing effect of Irbe-
sartan is lacking; however, administration of Irbesartan to
insulin resistant genetically obese Zucker rats significantly
Comorbidity pattern of patients with or without the metabolic syndrome (Total n = 14,200) Figure 2
Comorbidity pattern of patients with or without the metabolic syndrome (Total n = 14,200). PAD – peripheral arterial disease; 
PTCA – Percutaneous transluminal coronary angiography; MI – Myocardial infarction; TIA – Transient ischemic attack; LVH – 
Left ventricular hypertrophy, CHD – Coronary heart disease; Met (+) – Patients with the metabolic syndrome (doctors diag-



































* p < 0.0001 for the comparison
of all single risk factors vs. patients
without the metabolic syndromeCardiovascular Diabetology 2007, 6:12 http://www.cardiab.com/content/6/1/12
Page 7 of 11
(page number not for citation purposes)
decreased serum insulin levels and increased serum adi-
ponectin levels compared to control animals treated with
the vehicle. Fasting glucose levels were unaffected in this
model [18,19]. 2) Since PPARγ not only improves insulin
sensitivity but also improves the lipid metabolism, the
observed effects on the lipid profile may also be related to
PPARγ activation [20,21]. An increase in adiponectin lev-
els has also been observed with ARBs [18,22]; they have
been reported to be linked to an elevation in HDL choles-
terol, an observation that supports the present finding
[23]. On the other hand, in diabetic Zucker rats there was
no effect on triglycerides or body weight [19]. 3) Irbe-
sartan and other RAS blocking agents are more favorable
in terms of body weight development than beta-blockers
or diuretics. Even among the ARBs there may be a differ-
ence in body weight development as recently suggested by
Sugimoto and colleagues [24]. In line with this reasoning
a moderate reduction in weight loss cannot be ruled out
and Irbesartan may be particularly worthwhile for antihy-
pertensive treatment in overweight patients.
Another interesting observation is that the thiazide com-
ponent when given in low dose together with Irbesartan
did not lead to unfavorable consequences in terms of met-
abolic control. Whereas thiazide diuretics have proved to
be highly effective blood pressure agents [25], HCTZ is
known to increase insulin resistance and, in certain set-
tings, can lead to adverse metabolic changes as well as
increased plasminogen activator inhibitor-1, at least in
higher doses [26,27]. Consequently, its use has been dis-
couraged in susceptible populations such as patients with
diabetes [28]. In contrast, ARBs have been shown to have
beneficial effects on multiple components of the meta-
bolic syndrome [29], an observation consistent with pri-
mary links between angiotensin II and insulin resistance
[30]. Similarly HCTZ has been reported to abolish the
Table 1: Antihypertensive therapy at baseline and during follow-up
Baseline after switch after 3 month after 9 month
Metab (-) Metab (+) Metab (-) Metab (+) Metab (-) Metab (+) Metab (-) Metab (+)
Substance classes
none % 4.9 2.7 0.0 0.0 0.0 0.0 0.0 0.0
ACE-inhibitors % 48.2 59.3* 3.7 7.7* 3.5 7.6* 3.5 7.0*
Alpha-blockers % 3.2 4.1** 1.6 2.6* 1.5 2.6* 1.5 2.6*
ARBs % 4.0 4.7 98.9 99.8* 97.6 97.7 91.9 92.0
Beta-blockers % 44.3 49.3* 25.9 34.8* 25.3 33.7* 24.2 31.3*
Diuretics % 30.7 47.8* 7.0 14.4* 6.5 13.6* 6.0 12.4*
Calcium antagonists % 27.5 36.4* 13.3 22.7* 13.4 23.0* 13.0 21.8*
Irbesartan 75 mg % < 0.1 0.0 0.3 0.2 0.3 0.1** 0.3 0.1**
Irbesartan 150 mg % 0.5 0.4 11.0 5.8* 8.0 3.7* 7.5 3.2*
Irbesartan 300 mg % 0.1 0.2 29.8 22.0* 28.2 19.8* 25.2 17.9*
Irbesartan 150 mg/12,5 mg HCTZ % < 0.1 0.1 10.8 9.1** 8.9 6.6* 8.4 6.1*
Irbesartan 300 mg/12,5 mg HCTZ % 0.1 < 0.1 46.0 62.1* 50.4 66.0* 48.2 62.6*
Met (+) – Patients with the metabolic syndrome (doctors' diagnosis); Met (-) – Patients without the metabolic syndrome; statistical test applied: 
Chi2-test; * p < 0.0001 vs. patients without MS; ** p < 0.01 vs. patients without MS
Table 4: Most frequent serious side effects noted during the study (n)
Reported Side Effects Irbesartan Irbesartan/HCTZ
1 Cardiogenic shock 1 2
2 Cerebral infarction 1 1
3 Gastrointestinal hemorrhage 1 1
4 Metastatic bronchial carcinoma 1 1
5 Myocardial infarction 2 1
6 Rash 1 1
7 Tachyarrhythmia 1 1
8 Vertigo 1 1
out of a total of 14,200 patientsCardiovascular Diabetology 2007, 6:12 http://www.cardiab.com/content/6/1/12
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antiatherosclerotic effects exerted by inhibition of the
renin-angiotensin system with quinapril, at least in hyper-
cholesterolemic rabbit models [31]. Given the high pro-
portion of patients difficult to control with monotherapy
and the value of diuretics in a variety of patient popula-
tions, it is of particular importance to counterbalance the
untoward effects by using low dose combination therapy
with an ARB. Furthermore, there is clear evidence from
several endpoint trials including the LIFE study, that a
combination of thiazide diuretics with ARB results in an
effective reduction of cardiovascular risk and mortality in
hypertensive subjects [32].
In conclusion, there seems to be a quantitative difference
in the beneficial metabolic profile of Irbesartan between
patients with and without the metabolic syndrome. Par-
ticularly patients with the metabolic syndrome benefit
from the addition of Irbesartan to their antihypertensive
regimen, an effect that is seen less so in normal patients
but may even be less pronounced in diabetic patients, but
this topic still awaits further studies.
Table 3: Metabolic risk factors in metabolic syndrome patients with Irbesartan treatment alone or in combination with HCTZ
Irbesartan in patients with the metabolic syndrome1 Irbesartan/12.5 mg HCT in patients with the metabolic 
syndrome1
Components of the Met. Syn. Baseline 3 months 9 months Reduction † Baseline 3 months 9 months Reduction †
Blood pressure mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD
systolic mmHg 159.1 ± 12.9 137.8* ± 11.2 132.8* ± 10.1 -26.3 161.3 ± 13.2 139.0* ± 11.2 133.8* ± 10.1 -27.5
diastolic mmHg 93.4 ± 8.6 82.8* ± 7.2 80.4* ± 6.6 -13.0 95.0 ± 8.6 83.8* ± 7.4 80.9* ± 6.6 -14.1
Fasting plasma
glucose mg/dL 118.3 ± 29.9 111.8* ± 26.0 109.9* ± 25.1 -8.4 122.9 ± 29.8 115.4* ± 26.0 112.9* ± 24.7 -10.0
Abdominal obesity
men cm 109.9 ± 13.0 108.4* ± 12.2 107.5* ± 11.9 -2.4 112.0 ± 12.9 110.3* ± 12.3 108.8* ± 12.7 -3.2
women cm 99.3 ± 14.3 98.3* ± 14.3 98.1* ± 14.2 -1.2 101.5 ± 14.7 100.8* ± 14.7 99.8* ± 14.4 -1.7
Triglycerides mg/dL 212.3 ± 61.2 194.2* ± 56.7 183.7* ± 52.1 -28.6 221.5 ± 63.0 198.4* ± 55.3 187.4* ± 52.6 -34.1
HDL cholesterol
men mg/dL 42.2 ± 7.7 44.6* ± 7.3 45.8* ± 7.2 3.6 41.4 ± 7.5 44.0* ± 7.0 45.4* ± 6.8 4.0
women mg/dL 45.0 ± 7.2 47.8* ± 6.8 48.8* ± 6.5 3.8 44.2 ± 7.4 46.4* ± 6.9 47.6* ± 6.8 3.4
1 doctors' diagnosis; statistical test applied: t-test; * p < 0.0001; ** p < 0.05; † reduction versus baseline
Table 2: Metabolic risk factors in patients treated with Irbesartan with or without the metabolic syndrome
Patients without the metabolic syndrome1 Patients with the metabolic syndrome1
Components of the Met. Syn. Baseline 3 months 9 months Reduction † Baseline 3 months 9 months Reduction †
Blood pressure mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD
systolic mmHg 159.4 ± 13.3 136.8* ± 11.3 131.9* ± 10.0 -27.5 160.7 ± 13.4 139.1* ± 11.5 133.9* ± 10.5 -26.8
diastolic mmHg 93.7 ± 8.5 82.6* ± 7.5 79.9* ± 6.7 -13.8 94.3 ± 8.8 83.8* ± 7.6 80.8* ± 6.8 -13.5
Fasting plasma
glucose mg/dL 91.5 ± 13.6 91.8 ± 13.5 92.6** ± 15.0 1.1 120.9 ± 30.1 114.2* ± 26.3 111.9* ± 25.0 -9.0
Abdominal obesity
men cm 96.6 ± 10.2 96.1* ± 10.2 95.9* ± 10.1 -0.7 111.3 ± 12.8 109.9* ± 12.4 108.6* ± 12.6 -2.7
women cm 85.9 ± 11.9 85.5* ± 11.7 85.8** ± 11.8 -0.1 100.7 ± 14.6 100* ± 14.6 99.2* ± 14.3 -1.5
Triglycerides mg/dL 153.3 ± 42.2 151.9* ± 40.2 151.7* ± 41.1 -1.6 217.5 ± 62.5 196.6* ± 56.2 186.7* ± 53.2 -30.8
HDL cholesterol
men mg/dL 48.6 ± 6.2 49.2* ± 6.1 49.4* ± 6.2 0.8 41.8 ± 7.6 44.2* ± 7.1 45.6* ± 7.0 3.8
women mg/dL 52.2 ± 5.6 52.2 ± 5.8 51.9 ± 5.8 -0.3 44.4 ± 7.4 46.6* ± 6.9 47.7* ± 6.7 3.3
1 doctors' diagnosis; statistical test applied: t-test; * p < 0.0001; ** p < 0.05; † reduction versus baselineCardiovascular Diabetology 2007, 6:12 http://www.cardiab.com/content/6/1/12
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a&b: Number of metabolic risk factors present in metabolic syndrome patients with Irbesartan alone (Figure 3a) or in combi- nation with HCTZ (Figure 3b) Figure 3
a&b: Number of metabolic risk factors present in metabolic syndrome patients with Irbesartan alone (Figure 3a) or in combi-






















0 RF 0.0 0.7 1.4
1 RF 0.2 4.2 8.1
2 RF 4.7 19.9 24.8
3 RF 37.4 36.5 34.8
4 RF 40.5 30.5 23.8
5 RF 17.2 8.2 7.0
Baseline 3 month 9 month





















0 RF 0.0 0.4 0.7
1 RF 0.4 3.0 6.6
2 RF 3.8 14.6 20.2
3 RF 30.0 35.0 35.1
4 RF 42.2 33.5 28.2
5 RF 23.7 13.6 9.2
Baseline 3 month 9 month
p < 0.0001 p < 0.0001Cardiovascular Diabetology 2007, 6:12 http://www.cardiab.com/content/6/1/12
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Blood pressure lowering effect
The observed blood pressure lowering effect with Irbe-
sartan (for details see Table 2) is largely comparable to
previous results obtained in an open label study in Swit-
zerland in which 2621 previously treated or newly diag-
nosed patients achieved a mean blood pressure reduction
of 25/13 mmHg after 4 months of treatment with Irbe-
sartan (with or without HCTZ) [33]. It is slightly higher
than in a German phase IV study in overweight and obese
patients where blood pressure was lowered by 22/11
mmHg after 3 months of treatment [34], and in a recent
open phase IV trial in the US where the combination of
Irbesartan 300 mg with 25 mg HCTZ yielded a reduction
of 21.5/10.4 mmHg; however, this latter was of shorter
duration than the present study (18 weeks) [35]. The
present study differed from these studies in that a much
longer observation period was chosen, and between the 3-
month documentation (which would correspond to the
length of the studies cited above) and the 9-month there
was an average additional blood pressure reduction of
about 5 mmHg. Therefore the blood pressure lowering
effect of Irbesartan with or without HCTZ can be regarded
as clinically significant in the light of the need for aggres-
sive blood pressure management in this patient popula-
tion, where overall risk factor management is of foremost
importance.
Side effects
Irbesartan as monotherapy and in various combinations
was well tolerated, as evidenced by the low rate of AEs
(141 AEs in 88 patients, 0.62%). In previous open-label
observational studies with ARBs in the primary-care set-
ting, the respective rates had been considerably higher
[36,37]. Interestingly, the rate did not differ significantly
on comparison of the respective monotherapies or combi-
nation therapies with HCTZ.
Limitations
The present results have to be considered against the back-
ground of potential limitations. The study was not con-
trolled and therefore the contribution of placebo effects or
the withdrawal of other antihypertensive agents is
unknown. Second, in the absence of randomization pro-
cedures the influence of unknown biases, e.g. through
patient selection, cannot be assessed. Third, concomitant
medication influencing the metabolic profile (lipid lower-
ing agents and oral antidiabetic agents or insulin) have
not been documented in the present study, but since
patients were mostly non-diabetic the latter two treat-
ments are not likely to be prescribed in greater numbers.
Among the strengths of the study was the choice of the set-
ting. Observational studies in primary care, which include
typical patient groups and reflect current treatment
approaches, are useful for complementing the findings of
randomized controlled trials [38].
Conclusion
The present study demonstrates in a large patient cohort
with or without the metabolic syndrome that treatment
with an Irbesartan-based regimen for 9 months not only
results in a pronounced blood pressure reduction, but
also might have a favorable impact on important meta-
bolic parameters such as HDL cholesterol, triglycerides
and blood glucose. An Irbesartan-based regimen therefore
seems to be a rational treatment for patients with the met-
abolic syndrome.
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